Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
BMC Cancer ; 21(1): 227, 2021 Mar 06.
Article in English | MEDLINE | ID: mdl-33676443

ABSTRACT

INTRODUCTION: Although myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) - including chronic myeloid leukemia (CML) - and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are largely clinically distinct myeloid malignancies, epidemiological studies rarely examine them separately and often combine them with lymphoid malignancies, limiting possible etiological interpretations for specific myeloid malignancies. METHODS: We systematically evaluated the epidemiological literature on the four chemical agents (1,3-butadiene, formaldehyde, benzene, and tobacco smoking, excluding pharmaceutical, microbial and radioactive agents, and pesticides) classified by the International Agency for Research on Cancer as having sufficient epidemiological evidence to conclude that each causes "myeloid malignancies." Literature searches of IARC Monographs and PubMed identified 85 studies that we critically assessed, and for appropriate subsets, summarized results using meta-analysis. RESULTS: Only two epidemiological studies on 1,3-butadiene were identified, but reported findings were inadequate to evaluate specific myeloid malignancies. Studies on formaldehyde reported results for AML and CML - and not for MDS or MPN - but reported no increased risks. For benzene, several specific myeloid malignancies were evaluated, with consistent associations reported with AML and MDS and mixed results for CML. Studies of tobacco smoking examined all major myeloid malignancies, demonstrating consistent relationships with AML, MDS and MPN, but not with CML. CONCLUSIONS: Surprisingly few epidemiological studies present results for specific myeloid malignancies, and those identified were inconsistent across studies of the same exposure, as well as across chemical agents. This exercise illustrates that even for agents classified as having sufficient evidence of causing "myeloid malignancies," the epidemiological evidence for specific myeloid malignancies is generally limited and inconsistent. Future epidemiological studies should report findings for the specific myeloid malignancies, as combining them post hoc - where appropriate - always remains possible, whereas disaggregation may not. Furthermore, combining results across possibly discrete diseases reduces the chances of identifying important malignancy-specific causal associations.


Subject(s)
Carcinogens, Environmental/adverse effects , Epidemiologic Studies , Myelodysplastic Syndromes/epidemiology , Myelodysplastic-Myeloproliferative Diseases/epidemiology , Myeloproliferative Disorders/epidemiology , Causality , Humans , Myelodysplastic Syndromes/chemically induced , Myelodysplastic-Myeloproliferative Diseases/chemically induced , Myeloproliferative Disorders/chemically induced
3.
Regul Toxicol Pharmacol ; 82: 53-93, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27765718

ABSTRACT

Research suggests that exposure to ambient particulate matter (PM) may be associated with lung cancer; however, no mode of action (MoA) for this has been established. We applied a weight-of-evidence (WoE) approach to evaluate recent evidence from four realms of research (controlled human exposure, epidemiology, animal, and in vitro) to determine whether the overall evidence supports one or more MoAs by which PM could cause lung cancer. We evaluated three general MoAs: DNA damage and repair; other genotoxic effects, including mutagenicity and clastogenicity; and gene expression, protein expression, and DNA methylation. After assessing individual study quality, we evaluated the strength of the evidence within as well as across disciplines using a modified set of Bradford Hill considerations. We conclude that the overall WoE indicates it is plausible that PM of various size fractions may cause direct DNA damage, but the evidence is insufficient regarding the alternative MoAs we evaluated. More research is needed to determine whether DNA damage can lead to downstream events and, ultimately, lung cancer.


Subject(s)
Biomarkers, Tumor/genetics , Environmental Exposure/adverse effects , Environmental Pollutants/adverse effects , Lung Neoplasms/epidemiology , Lung Neoplasms/genetics , Particulate Matter/adverse effects , Animals , Biomarkers, Tumor/metabolism , DNA Damage , DNA Methylation/drug effects , DNA Repair/drug effects , Epidemiologic Methods , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lung Neoplasms/metabolism , Models, Animal , Mutagenesis , Risk Assessment , Risk Factors , Toxicity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...